Nomizo, T., H. Yamamoto, T. Murayama, H. Fukata, Y. Nakamura, M. Sonomura, A. Okuno, N. Kanda, C. Watanabe, and H. Kita. “Immune-Related Adverse Events Caused by Combined Immune Checkpoint Inhibitor Therapy With Nivolumab and Ipilimumab for Lung Cancer”. Trends in Immunotherapy, vol. 6, no. 1, Jan. 2022, doi:10.24294/ti.v6.i1.1386.